Stock Events

Stock Events

Genfit 

$4.85
83
+$0.12+2.54% Wednesday 20:59

Statistics

Day High
4.93
Day Low
4.37
52W High
5.35
52W Low
2.55
Volume
55,735
Avg. Volume
9,891
Mkt Cap
242.51M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2AprExpected
Q2 2025
Q1 2026
-0.24
0.25
0.73
1.21
Expected EPS
-0.0352353
Actual EPS
-0.0352353

Financials

3%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
140.85MRevenue
4.23MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GNFT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.55B
Madrigal Pharmaceuticals is focused on developing therapies for NASH, directly competing with Genfit's NASH programs.
Viking Therapeutics
VKTX
Mkt Cap4.02B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor to Genfit.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences has a strong pipeline in liver diseases, including NASH treatments, positioning it as a competitor to Genfit.
Agios Pharmaceuticals
AGIO
Mkt Cap2.06B
Agios Pharmaceuticals, though primarily focused on cancer and rare genetic diseases, has interests in metabolic disorders, potentially overlapping with Genfit's work.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.55M
Galmed Pharmaceuticals is developing therapies for liver diseases, including NASH, competing in the same space as Genfit.
Axsome Therapeutics
AXSM
Mkt Cap8.62B
Axsome Therapeutics, primarily focused on CNS disorders, has a broader portfolio that could intersect with metabolic diseases treatment, indirectly competing with Genfit.

About

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Show more...
CEO
Mr. Jean-Francois Mouney
Employees
180
Country
FR
ISIN
US3722791098

Listings

XETRA
DE
XUP.XETRA
LSE
GB
0QT6.LSE
XNAS
US
GNFTY
PA
FR
GNFT.PA

0 Comments

Share your thoughts

FAQ

What is Genfit stock price today?▼
The current price of GNFT is $4.85 USD — it has increased by +2.54% in the past 24 hours. Watch Genfit stock price performance more closely on the chart.
What is Genfit stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genfit stocks are traded under the ticker GNFT.
Is Genfit stock price growing?▼
GNFT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Genfit has showed a +78.64% increase.
What is Genfit market cap?▼
Today Genfit has the market capitalization of 242.51M
What is Genfit revenue for the last year?▼
Genfit revenue for the last year amounts to 140.85M USD.
What is Genfit net income for the last year?▼
GNFT net income for the last year is 4.23M USD.
How many employees does Genfit have?▼
As of April 09, 2026, the company has 180 employees.
In which sector is Genfit located?▼
Genfit operates in the Health Care sector.
When did Genfit complete a stock split?▼
Genfit has not had any recent stock splits.
Where is Genfit headquartered?▼
Genfit is headquartered in Loos, FR.